Abstract: Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids.

Abstract: Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids. Also disclosed are methods for identifying small D-peptides comprising aromatic D-amino acids that bind to proteins of interest.

Abstract: Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids. Also disclosed are methods for identifying small D-peptides comprising aromatic D-amino acids that bind to proteins of interest.

Abstract: The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. The invention further provides a method of prolonging the survival of tissue transplanted into a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. The invention also provides a method of treating an inflammatory response in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan.

Abstract: The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. The invention further provides a method of prolonging the survival of tissue transplanted into a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. The invention also provides a method of treating an inflammatory response in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan.

Abstract: The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence:Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr 1 5 10 ?SEQ ID NO 2!or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.

Abstract: The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.

Abstract: The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.

Abstract: The invention provides an antibody which reacts selectively with a transferrin homolog found in alcoholics but not in non-alcoholics. The invention also provides methods of making the antibody and hybridomas producing the antibody. Finally, the invention provides an immunoassay which utilizes the antibody to detect or quantitate the alcoholic transferrin homolog and a kit for an immunoassay which comprises a container of the antibody.

Abstract: The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.

Abstract: A method of binding aggregated immunoglobulin or immune complexes comprising contacting them with modified forms of C-reactive protein. The method may be employed for diagnostic and therapeutic purposes and to deplete fluids of aggregated immunoglobulin or immune complexes. Further, a method of reducing the levels of immune complexes in a mammal comprising administering modified-CRP to the mammal, and a method of binding immunoglobulins comprising contacting them with modified C-reactive protein. Also, a method of binding aggregated immunoglobulin or immune complexes comprising contacting them with antibody to neo-CRP, and a method of modifying C-reactive protein. Finally, a test kit for detecting or quantitating immune complexes and a device for removing aggregated immunoglobulin or immune complexes from fluids are disclosed.

Abstract: An immunoassay for a protein that is non-enzymatically glycosylated on the alpha amino group of its N-terminal amino acid, the immunoassay comprising: providing a sample containing the glycosylated protein; reacting the glycosylated protein with a reducing agent so that the sugar residue on the N-terminal amino acid is reduced; contacting the reduced glycosylated protein with an antibody directed to Glc-ol-X which is prepared by immunizing an animal with an immunogen of the formula (Glc-ol-X-L).sub.n -carrier; and detecting or quantitating the reduced glycosylated protein bound to the antibody. In the formula (Glc-ol-X-L).sub.

Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.

Abstract: The invention provides a method of screening for gastrointestinal cancer in a mammal comprising: (a) contacting a body fluid taken from the mammal with N3; (b) measuring the amount of antibody to N3 in the body fluid; and (c) determining if the amount of antibody measured in step (b) is higher than the amount of antibody to N3 normally present in the same type of body fluid taken from mammals of the same species that do not have cancer. The invention also provides kits for screening for gastrointestinal cancer in a mammal by measuring the mammal's level of antibodies to N3.

Abstract: The invention provides a fragment of Clq which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the Clq fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.

Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.

Abstract: A method of binding aggregated immunoglobulin or immune complexes comprising contacting them with serum amyloid P component ("SAP"). The invention also comprises methods of using SAP to detect or quantitate immune complexes and to deplete fluids of aggregated immunoglobulin or immune complexes for diagnostic or therapeutic purposes. Also provided is a test kit comprising SAP for detecting or quantitating immune complexes and a device for removing aggregated immunoglobulin or immune complexes from fluids.